A single course of lusutrombopag for multiple invasive procedures in cirrhosis-associated thrombocytopenia: A case series.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
04 Nov 2022
04 Nov 2022
Historique:
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
10
11
2022
Statut:
ppublish
Résumé
Lusutrombopag is a thrombopoietin receptor agonist which reduces the need for platelet transfusions before planned invasive procedures. A post hoc analysis of data from the registration trials observed that lusutrombopag-treated patients who achieved a platelet count > 50 × 109/L (responder patients) did so in a median of 6 days and the effect on platelet count lasted for nearly 3 weeks in total. Since patients with cirrhosis often require repeat invasive procedures, this kind of response-time trend sheds light on the possibility of placing more than one invasive procedure within a single course of lusutrombopag treatment. Platelet transfusion represents the gold standard in this setting, but is limited by the risk of adverse events and limited availability. We describe our experience with lusutrombopag in three patients with severe cirrhosis-associated thrombocytopenia who underwent multiple invasive procedures after a single course of treatment. The treatment schedule is lusutrombopag orally 3 mg/daily for 7 days and then a time window of 6 days (day 9-14) for the elective invasive procedure. All three patients achieved good response to lusutrombopag treatment and were able to undergone more invasive procedures in the same course of treatment without need of platelet transfusion. our preliminary experience supports the safety and the effectiveness of lusutrombopag in patients with severe cirrhosis-associated thrombocytopenia who underwent multiple invasive elective procedures after a single course.
Identifiants
pubmed: 36343065
doi: 10.1097/MD.0000000000031429
pii: 00005792-202211040-00048
pmc: PMC9646676
doi:
Substances chimiques
lusutrombopag
6LL5JFU42F
Cinnamates
0
Thiazoles
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31429Informations de copyright
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
MB and AG received personal fees from SOBI s.r.l and Shionogi B.V. The remaining authors have no conflicts of interest to disclose.
Références
Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017;37:778–93.
Estcourt LJ, Birchall J, Allard S, et alBritish Committee for Standards in Haematology. Guidelines for the use of platelet transfusions. Br J Haematol. 2017;176:365–94.
Delaney M, Wendel S, Bercovitz RS, et al. Biomedical excellence for safer transfusion (BEST) collaborative. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016;388:2825–36.
Katsube T, Ishibashi T, Kano T, Wajima T. Population pharmacokinetic and pharmacodynamic modeling of lusutrombopag, a newly developed oral thrombopoietin receptor agonist, in healthy subjects. Clin Pharmacokinet. 2016;55:1423–33.
Shirley M, McCafferty EH, Blair HA. Lusutrombopag: a review in thrombocytopenia in patients with chronic liver disease prior to a scheduled procedure. Drugs. 2019;79:1689–95.
Hidaka H, Kurosaki M, Tanaka H, et al. Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures (L-PLUS 1). Clin Gastroenterol Hepatol. 2019;17:1192–200.
Peck-Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2). Hepatology. 2019;70:1336–48.
Brown RS Jr, Imawari M, Izumi N, et al. Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag. JHEP Rep. 2021;3:100228.
Hirooka M, Ochi H, Hiraoka A, et al. The role of severe thrombocytopenia in preventing platelet count recovery in thrombocytopenic patients with chronic liver disease. J Gastroenterol Hepatol. 2020;35:299–304.
Takada H, Kurosaki M, Nakanishi H, et al. Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures. PLoS One. 2019;14:e0211122.
Uojima H, Arase Y, Itokawa N, et al. Relationship between response to lusutrombopag and splenic volume. World J Gastroenterol. 2018;24:5271–9.
Nishida Y, Kawaoka T, Imamura M, et al. Efficacy of lusutrombopag for thrombocytopenia in patients with chronic liver disease scheduled to undergo invasive procedures. Intern Med. 2021;60:829–37.
Takeuchi H, Furuichi Y, Yoshimasu Y, et al. The thrombopoietin receptor agonist lusutrombopag is effective for patients with chronic liver disease and impaired renal function. J Nippon Med Sch. 2021;87:325–33.
Tanaka K, Baba T, Yoshida M, et al. Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease: post hoc analysis of two placebo-controlled phase 3 trials. Curr Med Res Opin. 2022;38:303–10.
Cesar JM, Vecino AM. Survival and function of transfused platelets. Studies in two patients with congenital deficiencies of platelet membrane glycoproteins. Platelets. 2009;20:158–62.
Sano Y, Morimoto M, Kobayashi S, et al. Repeated lusutrombopag treatment for thrombocytopenia in patients with chronic liver disease. Digestion. 2021;102:654–62.
Kawaratani H, Tsuji Y, Ishida K, et al. Effect of three or more treatments with lusutrombopag in patients with cirrhotic thrombocytopenia: a retrospective single-center study. Hepatol Res. 2020;50:1101–5.
Ishikawa T, Okoshi M, Tomiyoshi K, et al. Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia. Hepatol Res. 2019;49:590–3.